nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—CYP3A4—Bexarotene—hematologic cancer	0.0373	0.0829	CbGbCtD
Hydralazine—CYP3A4—Lomustine—hematologic cancer	0.0347	0.0771	CbGbCtD
Hydralazine—CYP3A4—Busulfan—hematologic cancer	0.0347	0.0771	CbGbCtD
Hydralazine—CYP3A4—Thiotepa—hematologic cancer	0.0309	0.0687	CbGbCtD
Hydralazine—CYP3A4—Methoxsalen—hematologic cancer	0.024	0.0534	CbGbCtD
Hydralazine—CYP3A4—Bortezomib—hematologic cancer	0.0229	0.0508	CbGbCtD
Hydralazine—CYP3A4—Daunorubicin—hematologic cancer	0.0219	0.0486	CbGbCtD
Hydralazine—CYP3A4—Cytarabine—hematologic cancer	0.0193	0.0429	CbGbCtD
Hydralazine—CYP3A4—Teniposide—hematologic cancer	0.019	0.0422	CbGbCtD
Hydralazine—CYP3A4—Ifosfamide—hematologic cancer	0.0175	0.039	CbGbCtD
Hydralazine—CYP3A4—Imatinib—hematologic cancer	0.0167	0.0372	CbGbCtD
Hydralazine—CYP3A4—Ruxolitinib—hematologic cancer	0.0158	0.0351	CbGbCtD
Hydralazine—CYP3A4—Nilotinib—hematologic cancer	0.0152	0.0338	CbGbCtD
Hydralazine—CYP3A4—Vinorelbine—hematologic cancer	0.0151	0.0335	CbGbCtD
Hydralazine—CYP3A4—Triamcinolone—hematologic cancer	0.0138	0.0307	CbGbCtD
Hydralazine—CYP3A4—Dasatinib—hematologic cancer	0.0135	0.0299	CbGbCtD
Hydralazine—CYP3A4—Mitoxantrone—hematologic cancer	0.0133	0.0295	CbGbCtD
Hydralazine—CYP3A4—Betamethasone—hematologic cancer	0.0118	0.0263	CbGbCtD
Hydralazine—CYP3A4—Prednisolone—hematologic cancer	0.0117	0.026	CbGbCtD
Hydralazine—CYP3A4—Prednisone—hematologic cancer	0.011	0.0245	CbGbCtD
Hydralazine—CYP3A4—Irinotecan—hematologic cancer	0.0105	0.0233	CbGbCtD
Hydralazine—CYP3A4—Vinblastine—hematologic cancer	0.0093	0.0207	CbGbCtD
Hydralazine—CYP3A4—Vincristine—hematologic cancer	0.00914	0.0203	CbGbCtD
Hydralazine—CYP3A4—Etoposide—hematologic cancer	0.00838	0.0186	CbGbCtD
Hydralazine—AOC3—hematopoietic system—hematologic cancer	0.00733	0.0954	CbGeAlD
Hydralazine—RYR2—lung—hematologic cancer	0.00707	0.092	CbGeAlD
Hydralazine—CYP3A4—Dexamethasone—hematologic cancer	0.00689	0.0153	CbGbCtD
Hydralazine—RYR2—testis—hematologic cancer	0.00667	0.0868	CbGeAlD
Hydralazine—P4HA1—hematopoietic system—hematologic cancer	0.00586	0.0762	CbGeAlD
Hydralazine—CYP3A4—Doxorubicin—hematologic cancer	0.00571	0.0127	CbGbCtD
Hydralazine—AOC3—gonad—hematologic cancer	0.00557	0.0725	CbGeAlD
Hydralazine—AOC3—blood—hematologic cancer	0.00486	0.0632	CbGeAlD
Hydralazine—AOC3—bone marrow—hematologic cancer	0.0047	0.0611	CbGeAlD
Hydralazine—P4HA1—gonad—hematologic cancer	0.00446	0.058	CbGeAlD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—ANXA6—hematologic cancer	0.00434	0.0464	CbGpPWpGaD
Hydralazine—AOC3—lung—hematologic cancer	0.00426	0.0554	CbGeAlD
Hydralazine—RYR2—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.00418	0.0447	CbGpPWpGaD
Hydralazine—AOC3—testis—hematologic cancer	0.00402	0.0523	CbGeAlD
Hydralazine—P4HA1—blood—hematologic cancer	0.00388	0.0505	CbGeAlD
Hydralazine—P4HA1—bone marrow—hematologic cancer	0.00376	0.0489	CbGeAlD
Hydralazine—P4HA1—lung—hematologic cancer	0.0034	0.0443	CbGeAlD
Hydralazine—P4HA1—testis—hematologic cancer	0.00321	0.0418	CbGeAlD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—GJB3—hematologic cancer	0.00301	0.0321	CbGpPWpGaD
Hydralazine—AOC3—lymph node—hematologic cancer	0.00291	0.0379	CbGeAlD
Hydralazine—RYR2—SIDS Susceptibility Pathways—PBX1—hematologic cancer	0.0029	0.031	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—LEF1—hematologic cancer	0.00286	0.0306	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—FXYD6—hematologic cancer	0.00261	0.0279	CbGpPWpGaD
Hydralazine—RYR2—Stimuli-sensing channels—SGK1—hematologic cancer	0.00247	0.0265	CbGpPWpGaD
Hydralazine—P4HA1—lymph node—hematologic cancer	0.00233	0.0303	CbGeAlD
Hydralazine—RYR2—SIDS Susceptibility Pathways—TCF3—hematologic cancer	0.00229	0.0245	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—GJB6—hematologic cancer	0.00212	0.0226	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—GATA2—hematologic cancer	0.00211	0.0226	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—GJB2—hematologic cancer	0.00199	0.0213	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—ATP1B1—hematologic cancer	0.00199	0.0213	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—RET—hematologic cancer	0.00187	0.02	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—ATP1B1—hematologic cancer	0.00186	0.0199	CbGpPWpGaD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—CTNNA1—hematologic cancer	0.00184	0.0197	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—SGK1—hematologic cancer	0.00161	0.0173	CbGpPWpGaD
Hydralazine—RYR2—Ion channel transport—ATP4A—hematologic cancer	0.00161	0.0173	CbGpPWpGaD
Hydralazine—CYP3A4—hematopoietic system—hematologic cancer	0.00155	0.0202	CbGeAlD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—ITGA4—hematologic cancer	0.00154	0.0165	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—RGS2—hematologic cancer	0.00138	0.0148	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—RGS2—hematologic cancer	0.00134	0.0143	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—GSTO1—hematologic cancer	0.00132	0.0141	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.00132	0.0141	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—LPAR1—hematologic cancer	0.00128	0.0137	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.00127	0.0136	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.00126	0.0135	CbGpPWpGaD
Hydralazine—CYP3A4—Aflatoxin B1 metabolism—EPHX1—hematologic cancer	0.00125	0.0134	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.00121	0.013	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—PDE4B—hematologic cancer	0.00118	0.0126	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—ADCY7—hematologic cancer	0.00114	0.0122	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—ADCY7—hematologic cancer	0.00111	0.0118	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.00104	0.0111	CbGpPWpGaD
Hydralazine—CYP3A4—blood—hematologic cancer	0.00103	0.0134	CbGeAlD
Hydralazine—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—hematologic cancer	0.00102	0.0109	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—CAMK2D—hematologic cancer	0.00102	0.0109	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—CAMK2D—hematologic cancer	0.000986	0.0105	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.000978	0.0105	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—PRKCZ—hematologic cancer	0.000954	0.0102	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—CALR—hematologic cancer	0.000938	0.01	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000937	0.01	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—PRKCZ—hematologic cancer	0.000925	0.00989	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.00091	0.00973	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000743	0.00795	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.000741	0.00793	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—ABCC3—hematologic cancer	0.000723	0.00774	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.000689	0.00737	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—UGT1A1—hematologic cancer	0.00068	0.00727	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.000653	0.00699	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.00065	0.00695	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.000648	0.00693	CbGpPWpGaD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—PRKCG—hematologic cancer	0.000643	0.00688	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—PRKCG—hematologic cancer	0.000623	0.00667	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.000614	0.00657	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000601	0.00643	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.000562	0.00601	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.000562	0.00601	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.000562	0.00601	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000506	0.00541	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—FOS—hematologic cancer	0.000462	0.00494	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—CREB1—hematologic cancer	0.000462	0.00494	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CREB1—hematologic cancer	0.000459	0.00491	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL6R—hematologic cancer	0.000448	0.00479	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	0.000447	0.00478	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000444	0.00475	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—UGT1A1—hematologic cancer	0.000435	0.00465	CbGpPWpGaD
Hydralazine—CYP3A4—Farnesoid X Receptor  Pathway—NR0B2—hematologic cancer	0.000426	0.00455	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.000406	0.00434	CbGpPWpGaD
Hydralazine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—hematologic cancer	0.000398	0.00425	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC3—hematologic cancer	0.000396	0.00423	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000383	0.0041	CbGpPWpGaD
Hydralazine—CYP3A4—Irinotecan Pathway—ABCG2—hematologic cancer	0.000377	0.00403	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000372	0.00398	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.00037	0.00395	CbGpPWpGaD
Hydralazine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	0.000368	0.00394	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000362	0.00387	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—UGT1A1—hematologic cancer	0.000355	0.0038	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IL1B—hematologic cancer	0.000342	0.00366	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL1B—hematologic cancer	0.000341	0.00364	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—CASP3—hematologic cancer	0.00034	0.00364	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—JUN—hematologic cancer	0.000332	0.00355	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—JUN—hematologic cancer	0.00033	0.00353	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.000323	0.00345	CbGpPWpGaD
Hydralazine—CYP3A4—Farnesoid X Receptor  Pathway—FGF19—hematologic cancer	0.00032	0.00342	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—EP300—hematologic cancer	0.000305	0.00326	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	0.000288	0.00309	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—hematologic cancer	0.000288	0.00308	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—CYCS—hematologic cancer	0.000271	0.0029	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—TNF—hematologic cancer	0.000247	0.00264	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—NQO1—hematologic cancer	0.000244	0.00261	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC3—hematologic cancer	0.000239	0.00255	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC3—hematologic cancer	0.000227	0.00243	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	0.000226	0.00242	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—UGT1A1—hematologic cancer	0.000224	0.0024	CbGpPWpGaD
Hydralazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—hematologic cancer	0.000201	0.00215	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—IL6—hematologic cancer	0.000201	0.00214	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—IL6—hematologic cancer	0.0002	0.00213	CbGpPWpGaD
Hydralazine—CYP3A4—Estrogen metabolism—GSTM1—hematologic cancer	0.000187	0.002	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	0.000175	0.00187	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	0.000151	0.00162	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	0.000145	0.00155	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—ALB—hematologic cancer	0.000141	0.00151	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	0.000121	0.0013	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—hematologic cancer	0.000116	0.00124	CbGpPWpGaD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	0.000115	0.00123	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—SLC35B2—hematologic cancer	9.64e-05	0.00103	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—EPHX1—hematologic cancer	9.51e-05	0.00102	CbGpPWpGaD
Hydralazine—Feeling abnormal—Prednisolone—hematologic cancer	7.41e-05	0.000195	CcSEcCtD
Hydralazine—Anaemia—Prednisone—hematologic cancer	7.4e-05	0.000195	CcSEcCtD
Hydralazine—Headache—Carmustine—hematologic cancer	7.38e-05	0.000194	CcSEcCtD
Hydralazine—Dyspnoea—Triamcinolone—hematologic cancer	7.37e-05	0.000194	CcSEcCtD
Hydralazine—Rash—Alitretinoin—hematologic cancer	7.36e-05	0.000194	CcSEcCtD
Hydralazine—Agitation—Prednisone—hematologic cancer	7.35e-05	0.000194	CcSEcCtD
Hydralazine—Dermatitis—Alitretinoin—hematologic cancer	7.35e-05	0.000194	CcSEcCtD
Hydralazine—Thrombocytopenia—Betamethasone—hematologic cancer	7.34e-05	0.000193	CcSEcCtD
Hydralazine—Thrombocytopenia—Dexamethasone—hematologic cancer	7.34e-05	0.000193	CcSEcCtD
Hydralazine—Vomiting—Ifosfamide—hematologic cancer	7.33e-05	0.000193	CcSEcCtD
Hydralazine—Hypersensitivity—Cisplatin—hematologic cancer	7.33e-05	0.000193	CcSEcCtD
Hydralazine—Tachycardia—Dexamethasone—hematologic cancer	7.32e-05	0.000193	CcSEcCtD
Hydralazine—Tachycardia—Betamethasone—hematologic cancer	7.32e-05	0.000193	CcSEcCtD
Hydralazine—Headache—Alitretinoin—hematologic cancer	7.31e-05	0.000193	CcSEcCtD
Hydralazine—Diarrhoea—Gemcitabine—hematologic cancer	7.3e-05	0.000192	CcSEcCtD
Hydralazine—Nausea—Thalidomide—hematologic cancer	7.29e-05	0.000192	CcSEcCtD
Hydralazine—Dyspepsia—Triamcinolone—hematologic cancer	7.27e-05	0.000192	CcSEcCtD
Hydralazine—Rash—Ifosfamide—hematologic cancer	7.27e-05	0.000192	CcSEcCtD
Hydralazine—Dermatitis—Ifosfamide—hematologic cancer	7.27e-05	0.000191	CcSEcCtD
Hydralazine—Neuropathy peripheral—Doxorubicin—hematologic cancer	7.26e-05	0.000191	CcSEcCtD
Hydralazine—Dizziness—Irinotecan—hematologic cancer	7.24e-05	0.000191	CcSEcCtD
Hydralazine—Urticaria—Etoposide—hematologic cancer	7.24e-05	0.000191	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—hematologic cancer	7.22e-05	0.00019	CcSEcCtD
Hydralazine—Malaise—Prednisone—hematologic cancer	7.22e-05	0.00019	CcSEcCtD
Hydralazine—Body temperature increased—Etoposide—hematologic cancer	7.2e-05	0.00019	CcSEcCtD
Hydralazine—Conjunctivitis—Doxorubicin—hematologic cancer	7.2e-05	0.00019	CcSEcCtD
Hydralazine—Hepatitis—Epirubicin—hematologic cancer	7.19e-05	0.000189	CcSEcCtD
Hydralazine—Hypoaesthesia—Epirubicin—hematologic cancer	7.15e-05	0.000188	CcSEcCtD
Hydralazine—Vomiting—Vincristine—hematologic cancer	7.15e-05	0.000188	CcSEcCtD
Hydralazine—Anorexia—Betamethasone—hematologic cancer	7.15e-05	0.000188	CcSEcCtD
Hydralazine—Anorexia—Dexamethasone—hematologic cancer	7.15e-05	0.000188	CcSEcCtD
Hydralazine—Urticaria—Prednisolone—hematologic cancer	7.14e-05	0.000188	CcSEcCtD
Hydralazine—Rash—Vincristine—hematologic cancer	7.09e-05	0.000187	CcSEcCtD
Hydralazine—Dermatitis—Vincristine—hematologic cancer	7.09e-05	0.000187	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—hematologic cancer	7.06e-05	0.000186	CcSEcCtD
Hydralazine—Headache—Vincristine—hematologic cancer	7.05e-05	0.000186	CcSEcCtD
Hydralazine—Hypotension—Dexamethasone—hematologic cancer	7.01e-05	0.000185	CcSEcCtD
Hydralazine—Hypotension—Betamethasone—hematologic cancer	7.01e-05	0.000185	CcSEcCtD
Hydralazine—Nausea—Carmustine—hematologic cancer	7e-05	0.000184	CcSEcCtD
Hydralazine—Vomiting—Mitoxantrone—hematologic cancer	6.96e-05	0.000183	CcSEcCtD
Hydralazine—Vomiting—Irinotecan—hematologic cancer	6.96e-05	0.000183	CcSEcCtD
Hydralazine—Nausea—Alitretinoin—hematologic cancer	6.93e-05	0.000183	CcSEcCtD
Hydralazine—Agranulocytosis—Doxorubicin—hematologic cancer	6.91e-05	0.000182	CcSEcCtD
Hydralazine—Rash—Mitoxantrone—hematologic cancer	6.91e-05	0.000182	CcSEcCtD
Hydralazine—Rash—Irinotecan—hematologic cancer	6.91e-05	0.000182	CcSEcCtD
Hydralazine—Dermatitis—Irinotecan—hematologic cancer	6.9e-05	0.000182	CcSEcCtD
Hydralazine—Dermatitis—Mitoxantrone—hematologic cancer	6.9e-05	0.000182	CcSEcCtD
Hydralazine—Chills—Methotrexate—hematologic cancer	6.89e-05	0.000182	CcSEcCtD
Hydralazine—Headache—Irinotecan—hematologic cancer	6.86e-05	0.000181	CcSEcCtD
Hydralazine—Headache—Mitoxantrone—hematologic cancer	6.86e-05	0.000181	CcSEcCtD
Hydralazine—Nausea—Ifosfamide—hematologic cancer	6.85e-05	0.00018	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.83e-05	0.00018	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.83e-05	0.00018	CcSEcCtD
Hydralazine—Arthralgia—Prednisone—hematologic cancer	6.81e-05	0.000179	CcSEcCtD
Hydralazine—Myalgia—Prednisone—hematologic cancer	6.81e-05	0.000179	CcSEcCtD
Hydralazine—Feeling abnormal—Triamcinolone—hematologic cancer	6.81e-05	0.000179	CcSEcCtD
Hydralazine—Diarrhoea—Cisplatin—hematologic cancer	6.8e-05	0.000179	CcSEcCtD
Hydralazine—Anxiety—Prednisone—hematologic cancer	6.79e-05	0.000179	CcSEcCtD
Hydralazine—Vomiting—Gemcitabine—hematologic cancer	6.78e-05	0.000179	CcSEcCtD
Hydralazine—Paraesthesia—Betamethasone—hematologic cancer	6.73e-05	0.000177	CcSEcCtD
Hydralazine—Paraesthesia—Dexamethasone—hematologic cancer	6.73e-05	0.000177	CcSEcCtD
Hydralazine—Discomfort—Prednisone—hematologic cancer	6.73e-05	0.000177	CcSEcCtD
Hydralazine—Rash—Gemcitabine—hematologic cancer	6.73e-05	0.000177	CcSEcCtD
Hydralazine—Dermatitis—Gemcitabine—hematologic cancer	6.72e-05	0.000177	CcSEcCtD
Hydralazine—Hypersensitivity—Etoposide—hematologic cancer	6.71e-05	0.000177	CcSEcCtD
Hydralazine—Headache—Gemcitabine—hematologic cancer	6.68e-05	0.000176	CcSEcCtD
Hydralazine—Nausea—Vincristine—hematologic cancer	6.68e-05	0.000176	CcSEcCtD
Hydralazine—Flushing—Epirubicin—hematologic cancer	6.67e-05	0.000176	CcSEcCtD
Hydralazine—Hepatitis—Doxorubicin—hematologic cancer	6.65e-05	0.000175	CcSEcCtD
Hydralazine—Hypersensitivity—Prednisolone—hematologic cancer	6.62e-05	0.000174	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—hematologic cancer	6.62e-05	0.000174	CcSEcCtD
Hydralazine—Dyspepsia—Dexamethasone—hematologic cancer	6.6e-05	0.000174	CcSEcCtD
Hydralazine—Dyspepsia—Betamethasone—hematologic cancer	6.6e-05	0.000174	CcSEcCtD
Hydralazine—Urticaria—Triamcinolone—hematologic cancer	6.57e-05	0.000173	CcSEcCtD
Hydralazine—Body temperature increased—Triamcinolone—hematologic cancer	6.53e-05	0.000172	CcSEcCtD
Hydralazine—Oedema—Prednisone—hematologic cancer	6.53e-05	0.000172	CcSEcCtD
Hydralazine—Decreased appetite—Betamethasone—hematologic cancer	6.52e-05	0.000172	CcSEcCtD
Hydralazine—Decreased appetite—Dexamethasone—hematologic cancer	6.52e-05	0.000172	CcSEcCtD
Hydralazine—Nausea—Mitoxantrone—hematologic cancer	6.51e-05	0.000171	CcSEcCtD
Hydralazine—Nausea—Irinotecan—hematologic cancer	6.51e-05	0.000171	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Betamethasone—hematologic cancer	6.47e-05	0.00017	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	6.47e-05	0.00017	CcSEcCtD
Hydralazine—Chills—Epirubicin—hematologic cancer	6.45e-05	0.00017	CcSEcCtD
Hydralazine—Pruritus—Etoposide—hematologic cancer	6.45e-05	0.00017	CcSEcCtD
Hydralazine—Tachycardia—Prednisone—hematologic cancer	6.37e-05	0.000168	CcSEcCtD
Hydralazine—Nausea—Gemcitabine—hematologic cancer	6.34e-05	0.000167	CcSEcCtD
Hydralazine—Vomiting—Cisplatin—hematologic cancer	6.32e-05	0.000167	CcSEcCtD
Hydralazine—Rash—Cisplatin—hematologic cancer	6.27e-05	0.000165	CcSEcCtD
Hydralazine—Dermatitis—Cisplatin—hematologic cancer	6.26e-05	0.000165	CcSEcCtD
Hydralazine—Diarrhoea—Etoposide—hematologic cancer	6.23e-05	0.000164	CcSEcCtD
Hydralazine—Anorexia—Prednisone—hematologic cancer	6.22e-05	0.000164	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTO1—hematologic cancer	6.21e-05	0.000665	CbGpPWpGaD
Hydralazine—Ill-defined disorder—Methotrexate—hematologic cancer	6.2e-05	0.000163	CcSEcCtD
Hydralazine—Anaemia—Methotrexate—hematologic cancer	6.18e-05	0.000163	CcSEcCtD
Hydralazine—Feeling abnormal—Betamethasone—hematologic cancer	6.18e-05	0.000163	CcSEcCtD
Hydralazine—Feeling abnormal—Dexamethasone—hematologic cancer	6.18e-05	0.000163	CcSEcCtD
Hydralazine—Flushing—Doxorubicin—hematologic cancer	6.17e-05	0.000163	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTO1—hematologic cancer	6.13e-05	0.000656	CbGpPWpGaD
Hydralazine—Hypersensitivity—Triamcinolone—hematologic cancer	6.09e-05	0.00016	CcSEcCtD
Hydralazine—Malaise—Methotrexate—hematologic cancer	6.03e-05	0.000159	CcSEcCtD
Hydralazine—Dizziness—Etoposide—hematologic cancer	6.02e-05	0.000159	CcSEcCtD
Hydralazine—Muscle spasms—Epirubicin—hematologic cancer	6.02e-05	0.000158	CcSEcCtD
Hydralazine—Leukopenia—Methotrexate—hematologic cancer	5.99e-05	0.000158	CcSEcCtD
Hydralazine—Chills—Doxorubicin—hematologic cancer	5.97e-05	0.000157	CcSEcCtD
Hydralazine—Urticaria—Dexamethasone—hematologic cancer	5.96e-05	0.000157	CcSEcCtD
Hydralazine—Urticaria—Betamethasone—hematologic cancer	5.96e-05	0.000157	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.95e-05	0.000157	CcSEcCtD
Hydralazine—Dizziness—Prednisolone—hematologic cancer	5.94e-05	0.000156	CcSEcCtD
Hydralazine—Body temperature increased—Dexamethasone—hematologic cancer	5.93e-05	0.000156	CcSEcCtD
Hydralazine—Body temperature increased—Betamethasone—hematologic cancer	5.93e-05	0.000156	CcSEcCtD
Hydralazine—Nausea—Cisplatin—hematologic cancer	5.91e-05	0.000156	CcSEcCtD
Hydralazine—Paraesthesia—Prednisone—hematologic cancer	5.86e-05	0.000154	CcSEcCtD
Hydralazine—Pruritus—Triamcinolone—hematologic cancer	5.85e-05	0.000154	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—UGT1A1—hematologic cancer	5.84e-05	0.000625	CbGpPWpGaD
Hydralazine—Ill-defined disorder—Epirubicin—hematologic cancer	5.81e-05	0.000153	CcSEcCtD
Hydralazine—Vomiting—Etoposide—hematologic cancer	5.79e-05	0.000153	CcSEcCtD
Hydralazine—Anaemia—Epirubicin—hematologic cancer	5.78e-05	0.000152	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—UGT1A1—hematologic cancer	5.76e-05	0.000616	CbGpPWpGaD
Hydralazine—Agitation—Epirubicin—hematologic cancer	5.75e-05	0.000151	CcSEcCtD
Hydralazine—Dyspepsia—Prednisone—hematologic cancer	5.75e-05	0.000151	CcSEcCtD
Hydralazine—Rash—Etoposide—hematologic cancer	5.74e-05	0.000151	CcSEcCtD
Hydralazine—Dermatitis—Etoposide—hematologic cancer	5.74e-05	0.000151	CcSEcCtD
Hydralazine—Headache—Etoposide—hematologic cancer	5.71e-05	0.00015	CcSEcCtD
Hydralazine—Arthralgia—Methotrexate—hematologic cancer	5.69e-05	0.00015	CcSEcCtD
Hydralazine—Myalgia—Methotrexate—hematologic cancer	5.69e-05	0.00015	CcSEcCtD
Hydralazine—Decreased appetite—Prednisone—hematologic cancer	5.68e-05	0.000149	CcSEcCtD
Hydralazine—Rash—Prednisolone—hematologic cancer	5.67e-05	0.000149	CcSEcCtD
Hydralazine—Dermatitis—Prednisolone—hematologic cancer	5.66e-05	0.000149	CcSEcCtD
Hydralazine—Malaise—Epirubicin—hematologic cancer	5.64e-05	0.000149	CcSEcCtD
Hydralazine—Headache—Prednisolone—hematologic cancer	5.63e-05	0.000148	CcSEcCtD
Hydralazine—Discomfort—Methotrexate—hematologic cancer	5.62e-05	0.000148	CcSEcCtD
Hydralazine—Leukopenia—Epirubicin—hematologic cancer	5.6e-05	0.000148	CcSEcCtD
Hydralazine—Constipation—Prednisone—hematologic cancer	5.58e-05	0.000147	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—hematologic cancer	5.57e-05	0.000147	CcSEcCtD
Hydralazine—Palpitations—Epirubicin—hematologic cancer	5.53e-05	0.000146	CcSEcCtD
Hydralazine—Dizziness—Triamcinolone—hematologic cancer	5.46e-05	0.000144	CcSEcCtD
Hydralazine—Nausea—Etoposide—hematologic cancer	5.41e-05	0.000143	CcSEcCtD
Hydralazine—Feeling abnormal—Prednisone—hematologic cancer	5.38e-05	0.000142	CcSEcCtD
Hydralazine—Ill-defined disorder—Doxorubicin—hematologic cancer	5.37e-05	0.000141	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—hematologic cancer	5.35e-05	0.000141	CcSEcCtD
Hydralazine—Thrombocytopenia—Methotrexate—hematologic cancer	5.34e-05	0.000141	CcSEcCtD
Hydralazine—Nausea—Prednisolone—hematologic cancer	5.34e-05	0.000141	CcSEcCtD
Hydralazine—Arthralgia—Epirubicin—hematologic cancer	5.33e-05	0.00014	CcSEcCtD
Hydralazine—Myalgia—Epirubicin—hematologic cancer	5.33e-05	0.00014	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—hematologic cancer	5.32e-05	0.00014	CcSEcCtD
Hydralazine—Anxiety—Epirubicin—hematologic cancer	5.31e-05	0.00014	CcSEcCtD
Hydralazine—Pruritus—Betamethasone—hematologic cancer	5.31e-05	0.00014	CcSEcCtD
Hydralazine—Pruritus—Dexamethasone—hematologic cancer	5.31e-05	0.00014	CcSEcCtD
Hydralazine—Discomfort—Epirubicin—hematologic cancer	5.26e-05	0.000139	CcSEcCtD
Hydralazine—Vomiting—Triamcinolone—hematologic cancer	5.25e-05	0.000138	CcSEcCtD
Hydralazine—Malaise—Doxorubicin—hematologic cancer	5.22e-05	0.000138	CcSEcCtD
Hydralazine—Rash—Triamcinolone—hematologic cancer	5.21e-05	0.000137	CcSEcCtD
Hydralazine—Dermatitis—Triamcinolone—hematologic cancer	5.21e-05	0.000137	CcSEcCtD
Hydralazine—Anorexia—Methotrexate—hematologic cancer	5.2e-05	0.000137	CcSEcCtD
Hydralazine—Urticaria—Prednisone—hematologic cancer	5.19e-05	0.000137	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—hematologic cancer	5.18e-05	0.000136	CcSEcCtD
Hydralazine—Headache—Triamcinolone—hematologic cancer	5.18e-05	0.000136	CcSEcCtD
Hydralazine—Body temperature increased—Prednisone—hematologic cancer	5.16e-05	0.000136	CcSEcCtD
Hydralazine—CYP3A4—Tryptophan metabolism—MDM2—hematologic cancer	5.16e-05	0.000551	CbGpPWpGaD
Hydralazine—Diarrhoea—Betamethasone—hematologic cancer	5.13e-05	0.000135	CcSEcCtD
Hydralazine—Diarrhoea—Dexamethasone—hematologic cancer	5.13e-05	0.000135	CcSEcCtD
Hydralazine—Palpitations—Doxorubicin—hematologic cancer	5.12e-05	0.000135	CcSEcCtD
Hydralazine—Oedema—Epirubicin—hematologic cancer	5.11e-05	0.000135	CcSEcCtD
Hydralazine—Hypotension—Methotrexate—hematologic cancer	5.1e-05	0.000134	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—MTR—hematologic cancer	5.07e-05	0.000542	CbGpPWpGaD
Hydralazine—Thrombocytopenia—Epirubicin—hematologic cancer	5e-05	0.000132	CcSEcCtD
Hydralazine—Tachycardia—Epirubicin—hematologic cancer	4.98e-05	0.000131	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.97e-05	0.000131	CcSEcCtD
Hydralazine—Dizziness—Dexamethasone—hematologic cancer	4.96e-05	0.000131	CcSEcCtD
Hydralazine—Dizziness—Betamethasone—hematologic cancer	4.96e-05	0.000131	CcSEcCtD
Hydralazine—Arthralgia—Doxorubicin—hematologic cancer	4.93e-05	0.00013	CcSEcCtD
Hydralazine—Myalgia—Doxorubicin—hematologic cancer	4.93e-05	0.00013	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—hematologic cancer	4.91e-05	0.000129	CcSEcCtD
Hydralazine—Nausea—Triamcinolone—hematologic cancer	4.91e-05	0.000129	CcSEcCtD
Hydralazine—Paraesthesia—Methotrexate—hematologic cancer	4.9e-05	0.000129	CcSEcCtD
Hydralazine—Discomfort—Doxorubicin—hematologic cancer	4.87e-05	0.000128	CcSEcCtD
Hydralazine—Anorexia—Epirubicin—hematologic cancer	4.87e-05	0.000128	CcSEcCtD
Hydralazine—Dyspnoea—Methotrexate—hematologic cancer	4.87e-05	0.000128	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTT1—hematologic cancer	4.82e-05	0.000515	CbGpPWpGaD
Hydralazine—Hypersensitivity—Prednisone—hematologic cancer	4.81e-05	0.000127	CcSEcCtD
Hydralazine—Dyspepsia—Methotrexate—hematologic cancer	4.8e-05	0.000127	CcSEcCtD
Hydralazine—Hypotension—Epirubicin—hematologic cancer	4.77e-05	0.000126	CcSEcCtD
Hydralazine—Vomiting—Betamethasone—hematologic cancer	4.77e-05	0.000126	CcSEcCtD
Hydralazine—Vomiting—Dexamethasone—hematologic cancer	4.77e-05	0.000126	CcSEcCtD
Hydralazine—Decreased appetite—Methotrexate—hematologic cancer	4.74e-05	0.000125	CcSEcCtD
Hydralazine—Rash—Dexamethasone—hematologic cancer	4.73e-05	0.000125	CcSEcCtD
Hydralazine—Rash—Betamethasone—hematologic cancer	4.73e-05	0.000125	CcSEcCtD
Hydralazine—Oedema—Doxorubicin—hematologic cancer	4.73e-05	0.000124	CcSEcCtD
Hydralazine—Dermatitis—Dexamethasone—hematologic cancer	4.72e-05	0.000124	CcSEcCtD
Hydralazine—Dermatitis—Betamethasone—hematologic cancer	4.72e-05	0.000124	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.71e-05	0.000124	CcSEcCtD
Hydralazine—Headache—Dexamethasone—hematologic cancer	4.7e-05	0.000124	CcSEcCtD
Hydralazine—Headache—Betamethasone—hematologic cancer	4.7e-05	0.000124	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.65e-05	0.000123	CcSEcCtD
Hydralazine—Thrombocytopenia—Doxorubicin—hematologic cancer	4.63e-05	0.000122	CcSEcCtD
Hydralazine—Pruritus—Prednisone—hematologic cancer	4.62e-05	0.000122	CcSEcCtD
Hydralazine—Tachycardia—Doxorubicin—hematologic cancer	4.61e-05	0.000121	CcSEcCtD
Hydralazine—Paraesthesia—Epirubicin—hematologic cancer	4.59e-05	0.000121	CcSEcCtD
Hydralazine—Dyspnoea—Epirubicin—hematologic cancer	4.55e-05	0.00012	CcSEcCtD
Hydralazine—Anorexia—Doxorubicin—hematologic cancer	4.5e-05	0.000119	CcSEcCtD
Hydralazine—Feeling abnormal—Methotrexate—hematologic cancer	4.5e-05	0.000118	CcSEcCtD
Hydralazine—Dyspepsia—Epirubicin—hematologic cancer	4.5e-05	0.000118	CcSEcCtD
Hydralazine—Diarrhoea—Prednisone—hematologic cancer	4.47e-05	0.000118	CcSEcCtD
Hydralazine—Nausea—Dexamethasone—hematologic cancer	4.45e-05	0.000117	CcSEcCtD
Hydralazine—Nausea—Betamethasone—hematologic cancer	4.45e-05	0.000117	CcSEcCtD
Hydralazine—Decreased appetite—Epirubicin—hematologic cancer	4.44e-05	0.000117	CcSEcCtD
Hydralazine—Hypotension—Doxorubicin—hematologic cancer	4.42e-05	0.000116	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.41e-05	0.000116	CcSEcCtD
Hydralazine—Constipation—Epirubicin—hematologic cancer	4.37e-05	0.000115	CcSEcCtD
Hydralazine—Urticaria—Methotrexate—hematologic cancer	4.34e-05	0.000114	CcSEcCtD
Hydralazine—Dizziness—Prednisone—hematologic cancer	4.32e-05	0.000114	CcSEcCtD
Hydralazine—Body temperature increased—Methotrexate—hematologic cancer	4.31e-05	0.000114	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.31e-05	0.000113	CcSEcCtD
Hydralazine—Paraesthesia—Doxorubicin—hematologic cancer	4.24e-05	0.000112	CcSEcCtD
Hydralazine—Dyspnoea—Doxorubicin—hematologic cancer	4.21e-05	0.000111	CcSEcCtD
Hydralazine—Feeling abnormal—Epirubicin—hematologic cancer	4.21e-05	0.000111	CcSEcCtD
Hydralazine—Dyspepsia—Doxorubicin—hematologic cancer	4.16e-05	0.00011	CcSEcCtD
Hydralazine—Vomiting—Prednisone—hematologic cancer	4.15e-05	0.000109	CcSEcCtD
Hydralazine—Rash—Prednisone—hematologic cancer	4.12e-05	0.000108	CcSEcCtD
Hydralazine—Dermatitis—Prednisone—hematologic cancer	4.11e-05	0.000108	CcSEcCtD
Hydralazine—Decreased appetite—Doxorubicin—hematologic cancer	4.11e-05	0.000108	CcSEcCtD
Hydralazine—Headache—Prednisone—hematologic cancer	4.09e-05	0.000108	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.08e-05	0.000107	CcSEcCtD
Hydralazine—Urticaria—Epirubicin—hematologic cancer	4.06e-05	0.000107	CcSEcCtD
Hydralazine—Constipation—Doxorubicin—hematologic cancer	4.04e-05	0.000106	CcSEcCtD
Hydralazine—Body temperature increased—Epirubicin—hematologic cancer	4.04e-05	0.000106	CcSEcCtD
Hydralazine—Hypersensitivity—Methotrexate—hematologic cancer	4.02e-05	0.000106	CcSEcCtD
Hydralazine—Feeling abnormal—Doxorubicin—hematologic cancer	3.89e-05	0.000103	CcSEcCtD
Hydralazine—Nausea—Prednisone—hematologic cancer	3.88e-05	0.000102	CcSEcCtD
Hydralazine—Pruritus—Methotrexate—hematologic cancer	3.86e-05	0.000102	CcSEcCtD
Hydralazine—Hypersensitivity—Epirubicin—hematologic cancer	3.76e-05	9.91e-05	CcSEcCtD
Hydralazine—Urticaria—Doxorubicin—hematologic cancer	3.75e-05	9.89e-05	CcSEcCtD
Hydralazine—Body temperature increased—Doxorubicin—hematologic cancer	3.74e-05	9.84e-05	CcSEcCtD
Hydralazine—Diarrhoea—Methotrexate—hematologic cancer	3.73e-05	9.83e-05	CcSEcCtD
Hydralazine—Pruritus—Epirubicin—hematologic cancer	3.61e-05	9.52e-05	CcSEcCtD
Hydralazine—Dizziness—Methotrexate—hematologic cancer	3.61e-05	9.5e-05	CcSEcCtD
Hydralazine—Diarrhoea—Epirubicin—hematologic cancer	3.49e-05	9.2e-05	CcSEcCtD
Hydralazine—Hypersensitivity—Doxorubicin—hematologic cancer	3.48e-05	9.17e-05	CcSEcCtD
Hydralazine—Vomiting—Methotrexate—hematologic cancer	3.47e-05	9.14e-05	CcSEcCtD
Hydralazine—Rash—Methotrexate—hematologic cancer	3.44e-05	9.06e-05	CcSEcCtD
Hydralazine—Dermatitis—Methotrexate—hematologic cancer	3.44e-05	9.05e-05	CcSEcCtD
Hydralazine—Headache—Methotrexate—hematologic cancer	3.42e-05	9e-05	CcSEcCtD
Hydralazine—Dizziness—Epirubicin—hematologic cancer	3.38e-05	8.89e-05	CcSEcCtD
Hydralazine—Pruritus—Doxorubicin—hematologic cancer	3.34e-05	8.8e-05	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTP1—hematologic cancer	3.34e-05	0.000357	CbGpPWpGaD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTP1—hematologic cancer	3.29e-05	0.000352	CbGpPWpGaD
Hydralazine—Vomiting—Epirubicin—hematologic cancer	3.25e-05	8.55e-05	CcSEcCtD
Hydralazine—Nausea—Methotrexate—hematologic cancer	3.24e-05	8.54e-05	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—hematologic cancer	3.23e-05	8.52e-05	CcSEcCtD
Hydralazine—Rash—Epirubicin—hematologic cancer	3.22e-05	8.48e-05	CcSEcCtD
Hydralazine—Dermatitis—Epirubicin—hematologic cancer	3.22e-05	8.47e-05	CcSEcCtD
Hydralazine—Headache—Epirubicin—hematologic cancer	3.2e-05	8.43e-05	CcSEcCtD
Hydralazine—Dizziness—Doxorubicin—hematologic cancer	3.12e-05	8.23e-05	CcSEcCtD
Hydralazine—CYP3A4—Biological oxidations—GSTM1—hematologic cancer	3.07e-05	0.000328	CbGpPWpGaD
Hydralazine—Nausea—Epirubicin—hematologic cancer	3.03e-05	7.99e-05	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	3.03e-05	0.000324	CbGpPWpGaD
Hydralazine—Vomiting—Doxorubicin—hematologic cancer	3e-05	7.91e-05	CcSEcCtD
Hydralazine—Rash—Doxorubicin—hematologic cancer	2.98e-05	7.85e-05	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—hematologic cancer	2.98e-05	7.84e-05	CcSEcCtD
Hydralazine—Headache—Doxorubicin—hematologic cancer	2.96e-05	7.8e-05	CcSEcCtD
Hydralazine—Nausea—Doxorubicin—hematologic cancer	2.81e-05	7.39e-05	CcSEcCtD
Hydralazine—CYP3A4—Metabolism—FTCD—hematologic cancer	2.56e-05	0.000274	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GMPS—hematologic cancer	2.56e-05	0.000274	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PHYH—hematologic cancer	2.56e-05	0.000274	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SMPD3—hematologic cancer	2.34e-05	0.00025	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—B3GAT1—hematologic cancer	2.05e-05	0.000219	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ASNS—hematologic cancer	2.05e-05	0.000219	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—DCK—hematologic cancer	2.05e-05	0.000219	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HDC—hematologic cancer	1.94e-05	0.000207	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CDA—hematologic cancer	1.77e-05	0.00019	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PC—hematologic cancer	1.71e-05	0.000183	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.65e-05	0.000176	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GBA—hematologic cancer	1.65e-05	0.000176	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTAP—hematologic cancer	1.51e-05	0.000161	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—FHL2—hematologic cancer	1.34e-05	0.000144	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AGRN—hematologic cancer	1.32e-05	0.000141	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HMMR—hematologic cancer	1.25e-05	0.000134	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—IDH2—hematologic cancer	1.25e-05	0.000134	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ARNTL—hematologic cancer	1.18e-05	0.000126	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ACP5—hematologic cancer	1.14e-05	0.000122	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CA9—hematologic cancer	1.14e-05	0.000122	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOR2—hematologic cancer	1.13e-05	0.000121	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—IDH1—hematologic cancer	1.07e-05	0.000115	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTO1—hematologic cancer	1.06e-05	0.000114	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TXN—hematologic cancer	1.06e-05	0.000114	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCC3—hematologic cancer	1.06e-05	0.000114	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SPHK1—hematologic cancer	1.04e-05	0.000111	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	9.99e-06	0.000107	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	9.72e-06	0.000104	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CRABP1—hematologic cancer	9.72e-06	0.000104	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALOX5—hematologic cancer	9.47e-06	0.000101	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NUP98—hematologic cancer	9.17e-06	9.81e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ADCY7—hematologic cancer	8.91e-06	9.52e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOA3—hematologic cancer	8.91e-06	9.52e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NUP214—hematologic cancer	8.84e-06	9.46e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTR—hematologic cancer	8.66e-06	9.27e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCG2—hematologic cancer	8.66e-06	9.27e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ENO2—hematologic cancer	8.5e-06	9.09e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTT1—hematologic cancer	8.24e-06	8.81e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SDC1—hematologic cancer	8.05e-06	8.61e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CD44—hematologic cancer	6.85e-06	7.32e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NQO1—hematologic cancer	6.85e-06	7.32e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CYCS—hematologic cancer	6.48e-06	6.93e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	6.44e-06	6.89e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTP1—hematologic cancer	5.71e-06	6.11e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ABCB1—hematologic cancer	5.41e-06	5.78e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—GSTM1—hematologic cancer	5.25e-06	5.61e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NCOR1—hematologic cancer	5.25e-06	5.61e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MTHFR—hematologic cancer	4.64e-06	4.96e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	3.9e-06	4.17e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CREBBP—hematologic cancer	3.61e-06	3.86e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	3.43e-06	3.66e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—ALB—hematologic cancer	3.38e-06	3.62e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	3.24e-06	3.46e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	2.99e-06	3.19e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTEN—hematologic cancer	2.58e-06	2.76e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—EP300—hematologic cancer	2.46e-06	2.63e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.82e-06	1.95e-05	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKT1—hematologic cancer	1.49e-06	1.59e-05	CbGpPWpGaD
